Bausch Health Companies Inc(BHC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.96 | Insider Own | 11.4% | Shs Outstand | 373.9M | Perf Week | 0.47% |
| Market Cap | 2.37B | Forward P/E | 1.46 | EPS next Y | -4.81% | Insider Trans | -0.14% | Shs Float | 331.3M | Perf Month | 11.6% |
| Enterprise Value | 22.28B | PEG | - | EPS next Q | 1.27 | Inst Own | 63.68% | Short Float | 2.54% | Perf Quarter | 40.49% |
| Income | -1.10B | P/S | 0.22 | EPS this Y | 18.64% | Inst Trans | 2.15% | Short Ratio | 2.61 | Perf Half Y | 13.8% |
| Sales | 10.85B | P/B | - | EPS next 5Y | -4.45% | ROA | -4.22% | Short Interest | 8.40M | Perf YTD | -8.63% |
| Book/sh | -4.74 | P/C | 1.29 | EPS past 3/5Y | - | ROE | - | 52W High | -20.63% ($8.00) | Perf Year | 2.42% |
| Cash/sh | 4.91 | P/FCF | 1.68 | Sales past 3/5Y | 8.11% 5.04% | ROIC | -6.06% | 52W Low | 46.65% ($4.33) | Perf 3Y | -5.65% |
| Dividend Est. | - | EV/EBITDA | 5.71 | EPS Y/Y TTM | -1216.28% | Gross Margin | 63.02% | Volatility(W/M) | 3.42% 4.02% | Perf 5Y | -77.74% |
| Dividend TTM | - | EV/Sales | 2.05 | Sales Y/Y TTM | 10.09% | Oper. Margin | 25.17% | ATR (14) | 0.25 | Perf 10Y | -70.92% |
| Dividend Ex-Date | 2010/11/10 | Quick Ratio | 1.08 | EPS Q/Q | 72.02% | Profit Margin | -10.12% | RSI (14) | 59.1 | Recom | 2.83 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.44 | Sales Q/Q | 12.73% | SMA20 | 4.02% ($6.1) | Beta | 0.36 | Target Price | $7.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/10/28 | SMA50 | 2.86% ($6.17) | Rel Volume | 0.74 | Prev Close | $6.44 |
| Employees | 20300 | LT Debt/Eq | - | EPS/Sales Surpr. | 25.12% 7.26% | SMA200 | 11.46% ($5.7) | Avg Volume(3M) | 3.23M | Price | $6.35 |
| IPO | 1994/3/29 | Option/Short | Yes/Yes | Trades | 6266 | Volume | 2,401,582 | Change | -1.4% |
💊 This is a global pharmaceutical company that develops and sells a wide range of specialty medicines. It markets both specialty and general pharmaceuticals across multiple therapeutic areas, including gastrointestinal, dermatology, and neurology, and also holds a stake in an ophthalmology healthcare subsidiary. As a specialty pharmaceutical player with a diversified drug portfolio and a global business foundation, debt management is a key challenge for the stock.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
Next earnings report: October 28
1 days to go.
BHC keeps an operating profit but posts a net loss
Of every $100 in sales, $25.17 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +18.6% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $22. Peers typically go for $217. Compared with its own 1-year average, it is 14% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -77.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 63.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IBHL iShares iBonds 2032 Term High Yield and Income ETF 0.03% 
HYHG ProShares High Yield-Interest Rate Hedged ETF 0.02% 
XB BondBloxx B-Rated USD High Yield Corporate Bond ETF 0.01% 
EVHY Eaton Vance High Yield ETF 0.01% 
MYHB State Street My2028 High Yield Corporate Bond ETF 0.01% It ranks #20 of 83 in the industry
Based on market cap of $2B.
HCM#19 HUTCHMED (China) Limited ADR $2B PER 140.3 BHC#20 Bausch Health Companies Inc $2B PER - 
SUPN#21 Supernus Pharmaceuticals Inc $2B PER - 
PBH#22 Prestige Consumer Healthcare Inc $2B PER 13.5 
PRGO#23 Perrigo Company plc $2B PER - 
FAQ
What kind of company is BHC?
BHC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BHC?
The market cap of BHC is approximately $2.4B, ranking 1,895 within its sector.
What is the 52-week high and low for BHC?
BHC has recorded a 52-week high of $8.00 and a low of $4.33.
